GSA Capital Partners LLP Purchases 287,163 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

GSA Capital Partners LLP grew its stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 226.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 413,795 shares of the company's stock after buying an additional 287,163 shares during the period. GSA Capital Partners LLP owned approximately 1.43% of Aerovate Therapeutics worth $865,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in AVTE. Values First Advisors Inc. bought a new position in Aerovate Therapeutics in the 2nd quarter worth $26,000. Bank of New York Mellon Corp grew its position in shares of Aerovate Therapeutics by 69.9% in the second quarter. Bank of New York Mellon Corp now owns 46,988 shares of the company's stock valued at $78,000 after purchasing an additional 19,324 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Aerovate Therapeutics in the second quarter worth about $35,000. Quest Partners LLC lifted its position in shares of Aerovate Therapeutics by 610.2% during the 2nd quarter. Quest Partners LLC now owns 32,856 shares of the company's stock worth $55,000 after purchasing an additional 28,230 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in Aerovate Therapeutics during the 2nd quarter valued at approximately $53,000.

Aerovate Therapeutics Stock Down 1.2 %

AVTE opened at $2.53 on Friday. The stock's 50 day moving average price is $2.21 and its two-hundred day moving average price is $6.09. Aerovate Therapeutics, Inc. has a 12-month low of $1.25 and a 12-month high of $32.42.

Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.03. On average, sell-side analysts anticipate that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current year.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.